甲状腺癌不同治疗方法对可溶性白介素-2受体（SIL-2R）影响的结果比较

目的测定甲状腺癌患者不同治疗方法血清可溶性白介素-2受体（SIL-2R）的变化。方法用夹心法ELISA分别对甲状腺癌30例，甲状腺腺瘤20例，结节性甲状腺肿17例，正常对照20例进行血清SIL-2R含量测定。结果甲状腺癌患者血清中SIL-2R明显高于良性疾病组及对照组（P〈0．01）；甲状腺癌治疗后5d血清中SIL-2R较治疗前增高，可能与术前血清中SIL-2R高水平及手术早允机体免疫有关；治疗后30d基本降至正常；良性腺瘤组及结节性甲状腺肿组与对照组间无明显差异（P〉0.05）；甲状腺癌血清中SIL-2R升高与甲状腺癌的病理类型无明显关系。结论检测血清中SIL-2R含量对判别甲状腺癌治疗效果有一定临床意义。

A Comparison content of Soluble Interleukin-2 Receptor (SIL-2R) in teratment thyroid carcinoma by different methods

Objective To study the Soluble Interleukin-2 Receptor(SIL-2R) level in 67 patients with thyroid benign or malignant disease.Methods Enzyme linked Immunosorbent Assay(ELISA) method are applied to observe the content of SIL-2R in serum in disease group(67 cases) and control group(20 cases).Results Serum SIL-2R level in patients with thyroid carcinoma was obviously higher than benign disease group and control group( P <0.01). There was no significant difference between benign adenoma and nodular goiter and control group( P <0.05). Serum SIL-2R level in 5 d after treatment was higher than that before treatment in patients with thyroid carcinoma. It is probably associated with high serum SIL-2R level decreased essentially to normal in 30 d after treatment Serum high SIL-2R level is not correlated with the pathologic type in thyroid carcinoma. Conclusion To investigate the content of changes in serum SIL-2R from evaluating curativ eeffect had help in patients with thyroid carcinoma.